Neurofilament Light and Its Association With CNS Involvement in Patients With Classic Infantile Pompe Disease

Author(s):
M. J. Mackenbach, MD1; E. A.J. Willemse, PhD2-3; J. J.A. van den Dorpel, MD1; N. A.M.E. van der Beek, MD, PhD4; Jordi Díaz-Manera, MD, professor5-7; D. Rizopoulos, Professor, PhD8; Charlotte Teunissen2; Ans T van der Ploeg, MD, PhD1; J. M.P. van den Hout, MD, PhD1

Corresponding Author:
J. M.P. van den Hout; j.vandenhout@erasmusmc.nl

This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Affiliation Information for All Authors: 1. Center for Lysosomal and Metabolic Diseases, Department of Paediatrics, Erasmus University Medical Center, 3015 GD Rotterdam, the Netherlands; 2. Neurochemistry laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam University Medical Centres, VU University, 1081 HV Amsterdam, The Netherlands; 3. Departments of Biomedizin and Neurology, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), University Hospital Basel and University of Basel, 4031 Basel, Switzerland; 4. Center for Lysosomal and Metabolic Diseases, Department of Neurology, Erasmus University Medical Center, 3015 GD Rotterdam, the Netherlands; 5. John Walton Muscular Dystrophy Research Centre, Newcastle University, NE1 3BZ Newcastle upon Tyne, United Kingdom; 6. Neuromuscular Disorders Laboratory, Institut de recerca de l’hospital de la Santa Creu I Sant Pau, 08041 Barcelona, Spain; 7. Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), 28029 Madrid, Spain; 8. Department of Biostatistics & Department of Epidemiology, Erasmus University Medical Center, 3015 GD Rotterdam, the Netherlands

Equal Author Contribution:

Contributions:
M. J. Mackenbach: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data
E. A.J. Willemse: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Analysis or interpretation of data
J. J.A. van den Dorpel: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data
N. A.M.E. van der Beek: Drafting/revision of the manuscript for content, including medical writing for content; Analysis or interpretation of data
Jordi Díaz-Manera: Drafting/revision of the manuscript for content, including medical writing for content
D. Rizopoulos: Analysis or interpretation of data
Charlotte Teunissen: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data
Ans T van der Ploeg: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data
J. M.P. van den Hout: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data
Figure Count:
3

Table Count:
1

Search Terms:

Acknowledgment:
The authors would like to thank Marjolein Dremmen MD, who helped with the grading of the MRI scans.

Study Funding:
Research on Pompe disease at Erasmus MC is financially supported by the Prinses Beatrix Spierfonds, (project number W.TR19-02), For Wis(h)dom foundation, LSH-TKI (project number LSHM16008) and Stichting Ziekte van Pompe. Several of the authors of this publication are members of the European Pompe Consortium (EPOC), European Reference Networks for Hereditary Metabolic Disorders (Metab-ERN) and Rare Neuromuscular Diseases (EURO-NMD) and/or of the Netherlands Neuromuscular Center (NL-NMD). In addition, research by C.E.T. was supported by the European Commission [Marie Curie International Training Network, grant agreement no, 860197 (MIRIADE) and JPND], Health Holland, the Dutch Research Council (ZonMW), Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands and the Alzheimer Association. The authors confirm independence from the sponsors; the content of the article has not been influenced by the sponsors.
Disclosure:
M.J. Mackenbach reports no disclosures relevant to the manuscript. E.A.J. Willemse reports no disclosures relevant to the manuscript. J.A. van den Dorpel reports no disclosures relevant to the manuscript. N. A. M. E. van den Beek has received consulting fees, speaking fees, and fees for attending meetings and Advisory boards by Sanofi. J. D. Díaz-Manera has participated in Advisory Boards organized by Sanofi, Amicus, Astellas, Sarepta, and Lupin, has received honoraria for participating in symposiums organized by Sanofi, Amicus, and Sarepta, and has received funding for research by Sanofi, Spark, and Boehringer. D. Rizopoulous reports no disclosures relevant to the manuscript. C.E. Teunissen has a collaboration contract with ADx Neurosciences, Quanterix, and Eli Lilly, performed contract research or received grants from AC-Immune, Axon Neurosciences, Bioconnect, Bioorchestra, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, Grifols, Novo Nordisk, PeopleBio, Roche, Toyama, and Vivoryon. She serves on editorial boards of Medidact Neurologie/Springer, Alzheimer Research and Therapy, Neurology: Neuroimmunology & Neuroinflammation, and is editor of a Neuromethods book Springer. She had speaker contracts for Roche, Grifols, Novo Nordisk. A.T. van der Ploeg received funding for research, clinical trials, and advisory fees from Sanofi-Genzyme, Amicus Therapeutics, Biomarin, Ultragenix, Sarepta, Audentes, and Spark Therapeutics working on enzyme replacement therapy or next-generation therapies in the field of Pompe disease, other lysosomal storage diseases or neuromuscular disorders, under agreements with Erasmus MC University Medical Center and the relevant industry. J.M.P. van den Hout received funding for research, clinical trials, and advisory fees from Sanofi-Genzyme, Amicus Therapeutics, Biomarin, Sarepta, and Chiesi working on enzyme replacement therapy or next-generation therapies in the field of Pompe disease, other lysosomal storage diseases or neuromuscular disorders, under agreements with Erasmus MC University Medical Center and the relevant industry.

Preprint DOI:

Received Date:
2022-10-07

Accepted Date:
2023-04-18

Handling Editor Statement:
Submitted and externally peer reviewed. The handling editor was Associate Editor Courtney Wusthoff, MD, MS.
Abstract

Background and objectives: Enzyme replacement therapy (ERT) has substantially improved the outcome of classic infantile Pompe disease, an inheritable muscle disease previously fatal at infancy. However, under treatment, patients develop white matter abnormalities (WMA) and neurocognitive problems. Therefore, upcoming therapies also target the brain. Currently biomarkers reflecting CNS involvement are lacking. We aimed to study the association of Neurofilament Light and CNS involvement.

Methods: To investigate the potential of NfL, we analysed serum samples of patients with classic infantile Pompe disease who were treated with ERT. The samples were collected at ages of <1, 5 and 10 years, as well as around MRI scans. We compared the outcomes to levels in age and sex matched peers. Control samples were originally collected as part of routine blood work in children that underwent small surgeries and stored in the biobank of the Erasmus MC/ Sophia Children’s Hospital.

Results: We analysed 74 serum samples of 17 patients collected at ages ranging from 22 days to 21.2 years (1-8 samples per patients) and compared these to outcomes of 71 matched peers.

In the first year of age NfL levels in patients and controls were similar (10.3 vs. 11.0 pg/ml), but mixed linear model analysis showed a yearly increase of NfL of 6.0% in patients, compared to a decrease of 8.8% in controls (p < 0.001). Higher NfL was associated with lower IQ scores (p = 0.009) and lower processing speed scores (p = 0.001).

Discussion: We found significant differences in NfL levels between patients and controls, and a good association between NfL and cognition. NfL deserves further exploration as a biomarker for CNS involvement in patients with classic infantile Pompe disease.

Introduction

Pompe disease, also known as Glycogen Storage Disease type 2 (GSDII) is a metabolic myopathy caused by the lysosomal deficiency of acid alpha-glucosidase (GAA). This deficiency leads to the accumulation of glycogen most prominently in muscle cells, but to a lesser extent also in glial cells, astrocytes, and neurons in the central nervous system.
Patients with the classic infantile phenotype of Pompe disease have no residual enzyme activity and consequently, manifest the most severe phenotype of the disease. Untreated, these patients die before the age of one year due to cardiorespiratory failure.\textsuperscript{1,5,6} The approval of enzyme replacement therapy (ERT) in 2006 has significantly improved the survival of these patients and enabled them to achieve formerly unmet motor milestones such as the ability to stand and walk.\textsuperscript{7-9} Globally, the first treated patients with classic infantile disease are now in their twenties.\textsuperscript{10,11}

Neurocognitive development of ERT-treated patients is normal during the first years of life. However, in childhood and adolescence, neuroimaging unveils slowly progressive white matter abnormalities (WMA), while cognitive tests show a decrease of processing speed and in a subset of patients a more generalized cognitive decline.\textsuperscript{10,12-14} These symptoms are thought to be the result of the inability of ERT to cross the blood-brain barrier and subsequent accumulation of glycogen. This is also illustrated by the fact that autopsy studies in ERT-treated patients have shown glycogen accumulation in the brain.\textsuperscript{15} New treatments for classic infantile Pompe disease should therefore include the brain as an additional target.

To appreciate the effect of innovative therapies in upcoming phase 1-2 studies, it is important to fully understand the variability of CNS involvement in patients with classic infantile Pompe disease. Up till now the extent and rate of CNS involvement has been reported in a limited number of small cohorts of classic infantile patients and ranges from normal and stable to extensive and fast progressive\textsuperscript{10,12-14}. The methods currently used to monitor central nervous system (CNS) involvement have disadvantages. MRI scans are expensive and burdensome as these often require anaesthesia. The applied neuropsychological tests vary and are advised not to be performed more than once every one to two years due to a potential learning effect. In addition, both methods do not show evident deviations until later in life.\textsuperscript{10,12} Although, other authors describe a correlation between CK, urinary tetra-
saccharides and motor response to ERT, there are no early markers yet that reflect CNS damage. Body fluid biomarkers could be a cheap and easy to obtain alternative.

One such potential biomarker is Neurofilament Light (NfL). Neurofilament is a main protein of the axonal cytoskeleton which consists of different subunits, of which NfL is the most abundant. NfL can be measured in cerebral spinal fluid (CSF), but can also be reliably measured in blood nowadays, through Single Molecule Array (Simoa). Levels of NfL in serum, which is more readily available than CSF, are highly correlated with levels in CSF. Increased levels of NfL are associated with neuroaxonal and astroglial damage and correlate with disease activity in many paediatric neurological diseases, including Spinal Muscular Atrophy (SMA), Ceroid Lipofuscinosis type 2 (CLN2), Metachromatic Leukodystrophy (MLD), and X-linked Adrenoleukodystrophy (X-ALD). Unfortunately, reference values of NfL in both serum and CSF for the paediatric populations are lacking.

We hypothesize that NfL is increased in patients with classic infantile Pompe disease and may be correlated to clinical outcomes. In this study, we aimed to determine the potential of NfL as a biomarker for CNS involvement in patients with classic infantile Pompe disease, by comparing NfL levels in patients to age and sex matched controls, and by investigating the correlation of NfL levels with WMA on MRI and cognitive outcomes.

Materials and Methods

Patients With Classic Infantile Pompe Disease

All patients with classic infantile Pompe disease in the Netherlands are enrolled in a prospective standardized follow-up study. From this cohort, we included all patients who had an MRI brain scan between 1999 and September 19, 2020 (database lock). Classic infantile
Pompe disease was defined as symptom onset before the age of 6 months, presence of a hypertrophic cardiomyopathy, profound enzyme deficiency (<1% of normal values in fibroblasts or below reference values in leukocytes) and two severe pathogenic variants in the GAA gene (www.pompevariantdatabase.nl). \(^{24,25}\)

Patients were treated with alglucosidase alfa, at doses ranging from 20 mg/kg/2 weeks to 40 mg/kg/week. \(^8\)

As per protocol blood samples were taken twice to four times a year, cognitive evaluations were done once every 1-2 years, and MRI scans were performed at regular intervals every 1-3 years after 2016 and before 2016 occasionally. We analysed NfL levels in blood at set time points (at <1 year of age, if available before start of ERT and otherwise as close to start as possible, as well as at age 5 and 10 years) and around the time an MRI scan was available. We allowed for a window of one year difference between the time points at which the different measurements (NfL, cognitive tests and MRI scans) were taken.

**Control Samples**

Serum samples from age and sex matched controls were obtained from the biobank of the Sophia Children’s Hospital. These were taken as part of routine blood work in children that underwent small surgeries.

**NfL Analysis Using Simoa Technique**

Blood samples were stored in serum tubes at -80 degrees Celsius at the Erasmus Medical Centre’s Biobank until use. 250 µL serum was analysed in the Neurochemistry Lab of the department of Clinical Chemistry at the Amsterdam University Medical Centres (AUMC),
using the Simoa technique (Simoa HD-1) and the NF-light Kit according to the instructions.

Before measurement, samples were centrifuged for 10 minutes at room temperature at 1800g. Measurements were performed by blinded, certified technicians, in singlicate. Values are expressed in picogram per millilitre (pg/ml).

**MRI Scans**

We made MRI scans of the brain using a 1.5T or 3T system (EchoSpeed; GE Healthcare, Milwaukee, WI, USA), and a dedicated 8-channel head coil. MRIs were conducted according to a standardized protocol consisting of T1-weighted, T2-weighted, and fluid-attenuated inversion recovery images. MRIs were graded using the method described by Ebbink et al. (2018), recognizing four stages of involvement. Stage 0: no abnormalities. Stage 1: periventricular white matter (PVWM) involvement around the centrum semiovale. Stage 2: additional abnormalities in the subcortical white matter, internal capsule, external capsule and corpus callosum. Stage 3: extension to the u-fibres, basal ganglia, corticospinal tract, and/or infra-tentorial white matter. All MRIs were blinded, and independently graded by a paediatric neuro-radiologist (MD), a paediatric neurologist (JH), and a PhD student (JD). Discrepancies were solved by a consensus meeting.

**Cognitive Tests**

For patients aged \( \leq 6 \) years we used the Griffiths Mental Developmental Scales until the end of 2017 and the Wechsler Preschool and Primary Scale of Intelligence (WPPSI-III-NL) after 2017.
For children aged 6 years to 16 years and 11 months, we used the Wechsler Intelligence Scales for Children, third or fifth edition (WISC-III-NL or WISC-V-NL)\textsuperscript{29,30} and for patients older than 16 years and 11 months the Wechsler Adult Intelligence Score IV-NL (WAIS-IV-NL) was used.\textsuperscript{31} All neuropsychological tests measured either full scale intelligence quotients (IQ) or developmental quotients (DQ), while processing speed (PS) could be tested with the WPPSI, WISC and WAIS. The scores of all tests were compared to the normative data of the Dutch population. Mean score for the tests is 100, with a standard deviation (SD) of 15 points. A score above 85 is indicative of a normal development, a score between 84 and 70 of mild developmental delay, and a score below 70 of intellectual disability.

**Statistical Analyses**

Statistical analyses were performed using R, version 4.1.3 (2022-03-10, “One Push-Up”)

To account for the correlations between repeated measurements in individual patients, we used linear mixed-models. Interaction terms between models were tested using the likelihood-ratio test. Models’ assumptions were checked using residual plots. To correct for skewness of data, NfL levels were log-transformed. We used a mixed effects continuation ratio model for the ordinal data of the MRI brain scans.

The “nlme” and “GLMM adaptive” packages were used for the linear mixed-effects and continuation ratio models, the “lmerTest” package was used for testing of interaction terms.

Descriptive statistics, including median and range, were used to summarize demographic and clinical data. A p-value of <0.05 was assumed to be significant.
Standard Protocol Approvals, Registrations, and Patient Consents

Study protocols of studies in patients with Pompe disease and controls were approved by the Erasmus MC Medical Ethical Review Committee. Written informed consent was obtained from the patients as well as of controls and/or their parents.

Data Availability

Unpublished anonymized data within this article are available on reasonable request from a qualified investigator.

Results

General Characteristics

Seventeen patients with classic infantile Pompe disease were included (Table 1). Four (24%) patients were Cross-reactive immunological material (CRIM) negative, twelve (71%) were CRIM positive and one patient’s CRIM status was unknown. Median age at diagnosis was 2.3 months (range: 3 days – 5.7 months).

All patients were treated with recombinant human GAA (rhGAA). Their median age at start of ERT was 2.6 months (range: 4 days – 5.8 months). Median age at last NfL sample was 9.1 years (3.6 – 21.2 years), 4.8 years (range: 3.6 – 7.7) for CRIM negative patients and 9.9 years (range: 5.4 - 21.2) for CRIM positive patients. Additional clinical data can be found in Table 1.
NfL Levels in Patients and Controls

NfL blood levels were determined as close as possible to start of ERT (age <1) and at 5, and 10 years of age as well as at the time of MRI scans (Table 1). Five patients had baseline blood samples taken prior to initiation of ERT (age range: 0.2 – 0.4 years), ten had baseline samples taken thereafter (age range: 0.1 – 0.9 years), while two patients had no baseline sample available before the age of 1 year. Median NfL was 12.4 pg/ml (range 6.7 – 19.0) for ERT-naïve patients and 9.4 pg/ml (5.5 – 21.5) in patients with a baseline sample after the start of ERT.

A linear mixed effects model analysis including all samples (n=74) of the 17 patients (age range: 22 days - 21.2 years, 1 - 8 samples per patient) and samples of 71 unaffected age and sex matched controls (age range: 1.8 months – 16.1 years) showed that NfL levels in control patients decreased with 8.8% yearly, [95% CI 6.4, 11.2] while these increased in Pompe patients with 6.0% yearly, [95% CI 3.4, 8.0]. The difference between these two groups was significant (p < 0.001).

In our population, CRIM negative patients (open triangles) had 45%, [95 CI 8.4, 67.2], lower NfL levels compared with CRIM positive patients (Figure 1; closed circles). This difference was maintained after correction for age (p = 0.028).

Figure 1 shows all individual NfL samples and the locally estimated scatterplot smoothing (LOESS) regression curve as well as the 95%-confidence interval (shadows). The Figure shows that there is inter-individual and intra-individual variation.

Selection of three times points (age < 1 year, 5 and 10 years) showed the following. At first NfL assessment (age <1 year) the median NfL value in patients was 10.3 (range: 5.4 – 21.5,
n=15) pg/ml and 11.0 (6.7 – 49.4, n=15) pg/ml in controls; at age 5 years the median was 7.7 (4.5 – 21.3, n=16) pg/ml in patients and 6.4 (4.1 – 14.4, n=16) pg/ml in controls and at 10 years the median NfL value was 18.6 (5.2 - 41.1, n=8) and 9.8 (8.9 - 10.7, n=8) pg/ml in controls.

Association Between NfL and Brain Involvement on MRI

Forty-three MRI scans of 16 patients (age range: 2.7 - 21.2 years, 1 - 6 MRIs per patient) could be paired with 43 NfL blood samples that were taken around the same time (Figure 2). One patient with one MRI scan was excluded due to the unavailability of 3D sequences. One MRI scan was normal (stage 0; age 7.6 years). Six MRI scans were graded as stage 1 (median age: 5.4 years (2.7 – 7.5 years)). Nineteen scans were graded as stage 2 (median age: 9.1 years (4.6 – 12.9 years)), and 17 MRI scans were graded as stage 3 (median age: 13.2 years (4.4 – 21.2 years)). The NfL level of the patient with a normal MRI was 4.4 pg/ml. The median NfL of patients with stage 1 was 9.3 pg/ml (range: 6.1 – 97.4), 16.6 pg/ml (range: 5.3 – 37.6) of those with stage 2, and 21.3 pg/ml (range: 6.7 - 47.8) of patients with stage 3. Due to the instability of the mixed-effects continuation ratio model, the differences between the different groups could not be tested statistically.

Association Between NfL and Cognitive Outcomes

We compared NfL levels and cognitive scores (Figure 3). Forty-seven serum samples of 16 patients could be paired to 47 total IQ/DQ scores (age range: 0.16 – 21.2 years, 1-5 tests per patient), and 25 samples to 25 results of PS scTabores (age range: 5.3 – 21.2 years, 1-4 tests
per patient). A doubling of NfL corresponded to a decrease of 7.7 IQ points, \([95\% \ CI -13.2, -2.1, p = 0.009]\), and a decrease of 13.9 PS score points, \([95\% \ CI -20.8, -7.0, p = 0.001]\).

**Discussion**

We found that NfL levels increased in patients with classic infantile Pompe disease from age 0 to 21.2 years, whereas these decreased over time in healthy, age and sex matched controls at group level. In the first year of life, NfL levels were similar in both groups. After the age of 5 years, NfL levels of controls and patients deviated, NfL levels increased 6.0% per year in patients with Pompe disease, while they decreased by 8.8% per year in controls. With increasing NFL levels a significant decrease of IQ and PS scores was observed. Although there seemed to be a trend, no statistical relationship could be measured between NfL levels and MRI brain scores.

Cross-reactive immunological material (CRIM) negative patients, who produce no native GAA protein are thought to have a poorer prognosis than CRIM positive patients, who produce some inactive GAA protein. In our study, CRIM negative patients did not have higher NfL levels than CRIM positive patients, even after correction for age. As the number of CRIM negative patients \((n=4)\) in our study was low and their age young, this finding should be interpreted with caution.

Increased levels of NfL are predominantly found in diseases with neuroaxonal or astroglial injury. Therefore we hypothesize that the gradual increase of NfL in patients with classic infantile Pompe disease is the biochemical result of progressive glycogen accumulation and/or damage to the CNS, leading to leakage of NfL into CSF and serum.\(^\text{12}\) The elevation of NfL reflects the fact that ERT cannot pass the blood brain barrier and thus cannot reach glial cells, astrocytes, and neurons, where glycogen deposition has been found in autopsy studies.\(^\text{3,4}\)
Innovative therapies could provide a solution for the still unmet medical needs in classic infantile Pompe disease. Hematopoietic stem cell (HSPC)-mediated lentiviral gene therapy (LVGT) resulted in normalization of glycogen levels and neuro-inflammation in the brain of Pompe knock-out mice \(^{(32,33)}\). In other LSDs such as MPS I, II and CLN2 alternative approaches are effective such as intra-cerebral-ventricular ERT or IgG-ERT fusion proteins, where the IgG domain is a receptor-specific monoclonal antibody (MAb) that targets an endogenous BBB receptor transporter \(^{(34,35)}\). The findings from our study indicate that Nfl might be suitable as a biomarker both for follow-up and evaluation of emerging therapies that include the brain as a target.

**NfL Course in Individual Patients**

While Nfl levels increased with age in our cohort of patients with classic infantile patients on group level, we also observed inter-individual and intra-individual NfL variations, for which no clear explanation could be found. Similar unexplained intra-individual variations are also reported in other diseases such as CLN2 and MLD. More data, preferably in larger cohorts, are needed to provide context on the variability observed.

Nfl levels are also elevated in case of a peripheral neuropathy. A recent study in patient with classic infantile Pompe disease who learned to walk reported distal muscle weakness \(^{(36)}\). The pathophysiological process underlying the distal muscle weakness is not yet elucidated. This might be myopathic, neuropathic or a combination of both \(^{(37,38)}\). NfL increases in this cohort therefore might potentially partly be explained by peripheral neuropathy.

**Comparison to Other Lysosomal Storage Disorders**
The highest NfL level measured in our cohort of patients with classic infantile Pompe disease was 97.4 pg/ml. This was measured in a patient aged 4.1 years. In the oldest patient, aged 21.2 years, NFL level was measured at 29.2 pg/ml. These NfL levels were both considerably lower than those found in the more rapidly progressive MLD and CLN2.\textsuperscript{18,20} In these diseases, NfL levels were already high (measured around 100 - 300 pg/ml) around the time of diagnosis. Median age at diagnosis was 11.1 years in the study of MLD patients and 4.3 years in the study on CLN2 patients. In the study of MLD, NfL decreased in both treated and untreated patients. This was explained by the rapid progression of CNS damage and a concomitant rapid reduction of healthy brain tissue as a source of NfL release into serum. The decrease in treated and untreated patients with MLD complicates the interpretation of the effect of therapy using NfL as a biomarker.\textsuperscript{20} Our data show that the CNS progression in Pompe disease is different. Since the CNS involvement in Pompe disease is much slower, and NfL increased in our study over time from childhood through young adulthood in the absence of CNS-targeting therapy, we conclude that NfL holds promise as a biomarker to evaluate the effects of innovative future treatments targeting the brain.

**NfL in Healthy Age and Sex Matched Controls**

In our study the NfL levels in controls were relatively high during the first year and showed a decline thereafter during childhood and adolescence. It has been shown by others that during late adulthood NfL starts to increase again. The decline of NfL during childhood with increasing age was also observed by others and has been hypothesized to be related to factors such as ongoing myelination during the first years of life.\textsuperscript{20,39}

**Strength and imitations**
The strength of our study is the longitudinal follow-up combining NfL levels with cognitive tests and neuroimaging as well as the inclusion of a paediatric reference cohort.

A limitation is the small size of our cohort, due to the rarity of Pompe disease. Studies in larger groups of patients could provide additional insight in the role of factors such as CRIM status and enable statistical confirmation of the trends we observed between increased NfL levels and MRI brain scan scores. Additional these could provide further insight in the levels of NfL in patients with classic infantile Pompe disease in the first year of life, clarify at what age between the 5 and 10 years NfL levels in patients deviate significantly from normal and elucidate the extent and cause of inter- and intra-individual variations.

**Conclusion**

In conclusion, we found a significant difference between NfL levels of ERT treated patients with classic infantile Pompe disease and controls at group level during follow-up from infancy to young adulthood. In addition, we found that NfL levels were increased in patients with lower IQ and processing speed scores. This study indicates that NfL is a promising biomarker for CNS involvement in classic infantile Pompe disease and deserves additional research as a biomarker to monitor the effect of emerging treatments targeting the brain.
References


Table 1 Characteristics of the classic infantile Pompe patients

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients (% female)</td>
<td>17 (47%)</td>
</tr>
<tr>
<td>CRIM status; positive/negative/unknown</td>
<td>12/4/1</td>
</tr>
<tr>
<td>Median (range)</td>
<td></td>
</tr>
<tr>
<td>Age at diagnosis</td>
<td>2.3 months (3 days - 5.7 months)</td>
</tr>
<tr>
<td>Age at start ERT</td>
<td>2.6 months (4 days - 5.8 months)</td>
</tr>
<tr>
<td>Age at sample &lt;1 year</td>
<td>4.6 months (22 days - 11.1 months)¹</td>
</tr>
<tr>
<td>Age at last NFL sample</td>
<td>9.1 years (3.6 - 21.2 years)</td>
</tr>
<tr>
<td>No. of blood samples used for NFL measurement per patient</td>
<td>4 (1 - 8)</td>
</tr>
<tr>
<td>No. of cognitive tests per patient</td>
<td>2 (0 - 6)</td>
</tr>
<tr>
<td>Age at first IQ/DQ measurement</td>
<td>7.2 months (1.9 months - 10.6 years)²</td>
</tr>
<tr>
<td>Age at last IQ/DQ measurement</td>
<td>8.0 years (5.8 months - 21.2 years)³</td>
</tr>
<tr>
<td>IQ/DQ at first NFL assessment</td>
<td>89 (64 - 113)³</td>
</tr>
<tr>
<td>IQ/DQ at last NFL assessment</td>
<td>66 (45 - 102)³</td>
</tr>
<tr>
<td>Age at first PS measurement</td>
<td>6.8 years (5.3 - 10.6 years)³</td>
</tr>
<tr>
<td>Age at last PS measurement</td>
<td>8.5 years (5.3 - 21.2 years)³</td>
</tr>
<tr>
<td>PS at first cognitive assessment</td>
<td>89 (55 - 111)³</td>
</tr>
<tr>
<td>PS at last cognitive assessment</td>
<td>70 (45 - 111)³</td>
</tr>
<tr>
<td>Age at first MRI measurement</td>
<td>6.3 years (2.7 - 13.7 years)⁴</td>
</tr>
<tr>
<td>Age at last MRI measurement</td>
<td>8.7 years (4.6 - 21.2 years)⁴</td>
</tr>
<tr>
<td>No. of patients that died (at age)</td>
<td>3 (4.4; 14.5 and 15.5 years)</td>
</tr>
</tbody>
</table>

¹ Includes the patient who died at 14.5 years.
² Includes the patient who died at 15.5 years.
³ Includes the patient who died at 14.5 years.
⁴ Includes the patient who died at 15.5 years.
**Figure legends**

**Table 1 Characteristics of the classic infantile Pompe patient study population**

Neurofilament light = NfL; full scale intelligence quotient (IQ); developmental quotient (DQ); processing speed (PS)

Outcomes are presented as medians with ranges between brackets. ¹ Sample not available for two patients. ² No cognitive test data available for 1 patient. ³ Processing speed (PS) scores not available for 5 patients. ⁴ MRI brain scan data not available for 1 patient.

**Figure 1 NfL levels in classic infantile Pompe patients and controls**

Neurofilament Light (NfL) levels in classic infantile Pompe patients (red) and controls (blue), visualized with locally estimated scatterplot smoothing (LOESS) curves and the 95%-confidence intervals (shadows). The y-axis represents NfL in pg/ml on a logarithmic scale, and the x-axis represents the age in years. Controls are represented by open circles, cross-reactive immunological material (CRIM) negative Pompe patients by triangle symbols, CRIM positive Pompe patients by closed circles, and the patient whose CRIM status is unknown is signified by a square symbol.
Figure 2 NfL levels expressed against MRI brain scores

Neurofilament Light (NfL) levels in classic infantile Pompe patients expressed against MRI brain scores. The y-axis represents NfL levels in pg/ml, and the x-axis the MRI brain score.

![Figure 2](image)

Figure 3 Association between repeated measures of (A) Total IQ, (B) Processing Speed (PS) scores expressed and Neurofilament Light (NfL) levels in blood of classic infantile Pompe patients.

The y-axis represents IQ/PS scores, and the x-axis represents NfL levels in pg/ml on a logarithmic scale. Circular symbols represent measurements of the Griffiths Mental Developmental scales, triangles represent Wechsler Adult Intelligence Scale IV (WAIS-IV), square symbols represent scores of the Wechsler Intelligence Scales for Children III (WISC-III), and plus-symbols represent measurements of the Wechsler Preschool and Primary Scale of Intelligence (WPPSI-III-NL). The red continuous line represents the change in cognitive tests scores, with the blue dotted lines representing upper and lower limits.
Abbreviations:

CLN2 = ceroid lipofuscinosis type 2; CRIM = cross-reactive immunological material; DQ = developmental quotient; ERT = enzyme replacement therapy; GAA = acid alpha-glucosidase; GSDII = glycogen storage disease type II; IQ = full scale intelligence quotient; LSD = lysosomal storage disorder; MLD = metachromatic leukodystrophy; NfL = neurofilament light; PS = processing speed; PVWM = periventricular white matter; rhGAA = recombinant human acid alpha-glucosidase; SD = standard deviation; Simoa = single molecule array; SMA = spinal muscular atrophy; WAIS-IV = Wechsler adult intelligence score fourth edition; WISC-III/WISC-V = Wechsler intelligence scales for children third/fifth edition; WMA = white matter abnormalities; WPPSI = Wechsler preschool and primary scale of intelligence; X-ALD = X-linked adrenoleukodystrophy
Neurofilament Light and Its Association With CNS Involvement in Patients With Classic Infantile Pompe Disease
Neurology published online June 19, 2023
DOI 10.1212/WNL.0000000000207482

This information is current as of June 19, 2023

Updated Information & Services
including high resolution figures, can be found at:
http://n.neurology.org/content/early/2023/06/16/WNL.0000000000207482.full

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
All Pediatric
http://n.neurology.org/cgi/collection/all_pediatric
Metabolic disease (inherited)
http://n.neurology.org/cgi/collection/metabolic_disease_inherited
Muscle disease
http://n.neurology.org/cgi/collection/muscle_disease

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints
Information about ordering reprints can be found online:
http://n.neurology.org/subscribers/advertise